Why the study?
Current imaging modalities for venous thromboembolism are resource-intensive, time-consuming, and carry radiation risks, making sensitive and specific biomarkers imperative to enhance early detection.
Biomarkers offer a promising, less resource-intensive alternative to traditional imaging for the early detection and diagnosis of venous thromboembolism.
Answers are grounded in this paper and cite their sources.
Biomarkers may reduce imaging reliance in VTE diagnosis; leaves open prospective validation before clinical adoption.
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a life-threatening vascular disorder associated with significant morbidity and mortality. Prompt diagnosis is crucial for preventing fatal complications. Current clinical VTE diagnosis predominantly relies on imaging modalities such as compression ultrasound, computed tomography angiography (CTA), and magnetic resonance imaging (MRI). However, these techniques are resource-intensive, time-consuming, and may expose patients to radiation risks. Consequently, the development of highly sensitive and specific biomarkers is imperative to enhance early detection and guide therapeutic interventions. This review examines established and emerging biomarkers in venous thrombosis, evaluates current challenges, and outlines promising future directions for biomarker research in VTE.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: